XGEVA sales fall 27% ($155M) as biosimilar competition intensifies post-patent.

{
  "signal_id": "e2c7e388-efc5-42d0-8811-a2bc4b5e55bd",
  "signal_type": "sec-10q",
  "signal_subtype": "competitorNamed",
  "detected_at": "2026-05-05T08:48:22.5+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "detail": "Global XGEVA sales declined from $566M to $411M year-over-year due to a 19% drop in volume and lower prices. Similar to Prolia, Amgen anticipates 'accelerated sales erosion' as biosimilars enter the market, compounding the company's revenue challenges from patent cliffs.",
    "metrics": {
      "pct": -0.27,
      "timeframe": "current_quarter",
      "pct_context": "Year-over-year change in Total XGEVA sales for Q1",
      "dollar_context": "Year-over-year decrease in Total XGEVA sales for Q1",
      "dollar_millions": 155
    },
    "summary": "XGEVA sales fall 27% ($155M) as biosimilar competition intensifies post-patent.",
    "excerpts": "The decrease in global XGEVA sales for the three months ended March 31, 2026 was driven by lower volume of 19% and lower net selling price.",
    "relevance": 0.9,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/318154/000031815426000057/amgn-20260331.htm",
    "filing_date": "2026-04-30",
    "filing_year": 2026,
    "fiscal_year": 0,
    "fiscal_year_end": "03/31",
    "sales_relevance": "Competitive intelligence",
    "signal_category": "market",
    "regions_mentioned": [
      "U.S.",
      "ROW"
    ],
    "technologies_mentioned": [
      "biosimilars"
    ]
  }
}

curl https://signals.autobound.ai/v1/signals/e2c7e388-efc5-42d0-8811-a2bc4b5e55bd \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"amgen.com","limit":20}'